Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 2/2006

01.02.2006 | Original Article

Analysis of cytotoxicities of platinum compounds

verfasst von: Jerry Goodisman, Douglas Hagrman, Kirk A. Tacka, Abdul-Kader Souid

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 2/2006

Einloggen, um Zugang zu erhalten

Abstract

Extent of DNA platination, loss of cell viability, DNA fragmentation, and impairment of cellular mitochondrial oxygen consumption are measures of drug cytotoxicity. We measured and compared these effects for cisplatin, oxaliplatin and carboplatin. Because reaction with intracellular thiols may be responsible for drug resistance, we also determined the rates of Pt drug reactions with metallothionein. Jurkat cells were exposed at 37°C to 25 μM Pt drugs for 3 h. Pt-DNA adducts were determined at the end of the incubation period by atomic absorption spectroscopy. Viability, DNA fragmentation, and cellular respiration (μM O2/min/106 cells) were determined 24 h post drug exposure. The average amount of Pt-DNA adducts (Pt atoms/106 nucleotides) produced by cisplatin was 43.4, by oxaliplatin 4.8 and by carboplatin 1.5. Cisplatin decreased the rate of respiration by ~63% and oxaliplatin by ~37%. DNA fragmentation by cisplatin and oxaliplatin was very similar. Carboplatin produced an unnoticeable effect on cellular respiration, and only ~10% of the DNA fragmentation was produced by cisplatin or oxaliplatin. Although, for a given drug, all four measures of cytotoxicity were proportional, this did not hold for comparisons between the drugs. The rate constants (M−1 s−1) for reaction of cisplatin, oxaliplatin and carboplatin with Cd/Zn thionein were 0.75, 0.44 and 0.012, respectively. For comparison, the rate constants (M−1 s−1) for reaction of cisplatin, oxaliplatin and carboplatin with glutathione were 0.027, 0.038 and 0.0012, respectively. The low reactivity of carboplatin with metallothionein and glutathione suggests that its low cytotoxic activities are not due to reaction of Pt2+ with cellular thiols. Despite a tenfold difference in Pt-DNA adducts between cisplatin and oxaliplatin, the cytotoxicities of these compounds are very similar, suggesting that oxaliplatin lesions are more potent than cisplatin lesions. The results demonstrate a large influence of the ligands occupying Pt coordination spheres on the chemical and biologic activities of Pt drugs.
Literatur
1.
Zurück zum Zitat Allison DC, Ridolpho P (1980) Use of a trypan blue assay to measure the deoxyribonucleic acid content and radioactive labeling of viable cells. J Histochem Cytochem 28:700–703PubMed Allison DC, Ridolpho P (1980) Use of a trypan blue assay to measure the deoxyribonucleic acid content and radioactive labeling of viable cells. J Histochem Cytochem 28:700–703PubMed
2.
Zurück zum Zitat Berners-Price SJ, Kuchel PW (1990) Reaction of cis- and trans-[PtCl2 (NH3)2] with reduced glutathione, studied by 1H, 13C, 195Pt and 15N-{1H} DEPT NMR. J Inorg Biochem 38:305–326CrossRef Berners-Price SJ, Kuchel PW (1990) Reaction of cis- and trans-[PtCl2 (NH3)2] with reduced glutathione, studied by 1H, 13C, 195Pt and 15N-{1H} DEPT NMR. J Inorg Biochem 38:305–326CrossRef
3.
Zurück zum Zitat Braddock PD, Connors TA, Jones M, Khokhar AR, Melzack DH, Tobe ML (1975) Structure and activity relationships of platinum complexes with anti-tumour activity. Chem-Biol Intera 11:145–161CrossRef Braddock PD, Connors TA, Jones M, Khokhar AR, Melzack DH, Tobe ML (1975) Structure and activity relationships of platinum complexes with anti-tumour activity. Chem-Biol Intera 11:145–161CrossRef
4.
Zurück zum Zitat Brady HR, Kone BC, Stromski ME, Zeidel ML, Giebisch G, Gullans SR (1990) Mitochondrial injury: an early event in cisplatin toxicity to renal proximal cells. Am J Physiol 258:F1181–F1187PubMed Brady HR, Kone BC, Stromski ME, Zeidel ML, Giebisch G, Gullans SR (1990) Mitochondrial injury: an early event in cisplatin toxicity to renal proximal cells. Am J Physiol 258:F1181–F1187PubMed
5.
Zurück zum Zitat Cohen GM (1997) Caspases: the executioners of apoptosis. Biochem J 326:1–16PubMed Cohen GM (1997) Caspases: the executioners of apoptosis. Biochem J 326:1–16PubMed
6.
Zurück zum Zitat Corden BJ, Fine RL, Ozols RF, Collins JM (1985) Clinical pharmacology of high-dose cisplatin. Cancer Chemother Pharmacol 14:38–41CrossRefPubMed Corden BJ, Fine RL, Ozols RF, Collins JM (1985) Clinical pharmacology of high-dose cisplatin. Cancer Chemother Pharmacol 14:38–41CrossRefPubMed
7.
Zurück zum Zitat Dabrowiak JC, Goodisman J, Souid A-K (2002) Kinetic study of the reaction of cisplatin with thiols. Drug Metabol Dispos 30:1378–1384CrossRef Dabrowiak JC, Goodisman J, Souid A-K (2002) Kinetic study of the reaction of cisplatin with thiols. Drug Metabol Dispos 30:1378–1384CrossRef
8.
Zurück zum Zitat Dedon PC, Borch RF (1987) Characterization of the reactions of platinum antitumor agents with biologic and non-biologic sulfur-containing nucleophiles. Biochem Pharmacol 36:1955–1964PubMedCrossRef Dedon PC, Borch RF (1987) Characterization of the reactions of platinum antitumor agents with biologic and non-biologic sulfur-containing nucleophiles. Biochem Pharmacol 36:1955–1964PubMedCrossRef
9.
Zurück zum Zitat Ehrsson H, Wallin I, Yachnin J (2002) Pharmacokinetics of oxaliplatin in humans. Med Oncol 19:261–265CrossRefPubMed Ehrsson H, Wallin I, Yachnin J (2002) Pharmacokinetics of oxaliplatin in humans. Med Oncol 19:261–265CrossRefPubMed
10.
Zurück zum Zitat Gao W-G, Pu S-P, Liu W-P, Liu Z-D, Yang Y-K (2003) The aquation of oxaliplatin and the effect of acid. Acta Pharmaceutica Sinica 38:223–226PubMed Gao W-G, Pu S-P, Liu W-P, Liu Z-D, Yang Y-K (2003) The aquation of oxaliplatin and the effect of acid. Acta Pharmaceutica Sinica 38:223–226PubMed
11.
Zurück zum Zitat Gelasco A, Lippard SJ (1999) Anticancer activity of cisplatin and related compounds. Top Biol Inorg Chem 1:1–43 Gelasco A, Lippard SJ (1999) Anticancer activity of cisplatin and related compounds. Top Biol Inorg Chem 1:1–43
12.
Zurück zum Zitat Go RS, Adjei AA (1999) Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17:409–422PubMed Go RS, Adjei AA (1999) Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17:409–422PubMed
13.
Zurück zum Zitat Gong J, Traganos F, Darzynkiewicz Z (1994) A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry. Anal Biochem 218:314–319CrossRefPubMed Gong J, Traganos F, Darzynkiewicz Z (1994) A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry. Anal Biochem 218:314–319CrossRefPubMed
14.
Zurück zum Zitat Gonzalez VM, Fuertes MA, Alonso C, Perez JM (2001) Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 59:657–663PubMed Gonzalez VM, Fuertes MA, Alonso C, Perez JM (2001) Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 59:657–663PubMed
15.
Zurück zum Zitat Green TJ, Wilson DF, Vanderkooi JM, DeFeo AP (1988) Phosphorimeters for analysis of decay profiles and real time monitoring of exponential decay and oxygen concentrations. Anal Biochem 174:73–79CrossRefPubMed Green TJ, Wilson DF, Vanderkooi JM, DeFeo AP (1988) Phosphorimeters for analysis of decay profiles and real time monitoring of exponential decay and oxygen concentrations. Anal Biochem 174:73–79CrossRefPubMed
16.
Zurück zum Zitat Hagrman D, Goodisman J, Dabrowiak JC, Souid A-K (2003) Kinetic study on the reaction of cisplatin with metallothionein. Drug Metabol Dispos 31:916–923CrossRef Hagrman D, Goodisman J, Dabrowiak JC, Souid A-K (2003) Kinetic study on the reaction of cisplatin with metallothionein. Drug Metabol Dispos 31:916–923CrossRef
17.
Zurück zum Zitat Hagrman D, Goodisman J, Souid A-K (2004) Kinetic study on the reaction of platinum drugs with glutathione. J Pharmacol Exp Therap 308:658–666CrossRef Hagrman D, Goodisman J, Souid A-K (2004) Kinetic study on the reaction of platinum drugs with glutathione. J Pharmacol Exp Therap 308:658–666CrossRef
19.
Zurück zum Zitat Henkle KM, Turchi JJ (1997) Induction of apoptosis in cisplatin-sensitive and -resistant human ovarian cancer cell lines. Cancer Res 57:4488–4497PubMed Henkle KM, Turchi JJ (1997) Induction of apoptosis in cisplatin-sensitive and -resistant human ovarian cancer cell lines. Cancer Res 57:4488–4497PubMed
20.
Zurück zum Zitat Johnson SW, Swiggard PA, Handel LM, Brennan JM, Godwin AK, Ozols RF, Hamilton TC (1994) Relationship between platinum-DNA adduct formation and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells. Cancer Res 54:5911–5916PubMed Johnson SW, Swiggard PA, Handel LM, Brennan JM, Godwin AK, Ozols RF, Hamilton TC (1994) Relationship between platinum-DNA adduct formation and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells. Cancer Res 54:5911–5916PubMed
21.
Zurück zum Zitat Kartalou M, Essigmann JM (2001) Mechanisms of resistance to cisplatin. Mutation Res 478:23–43PubMed Kartalou M, Essigmann JM (2001) Mechanisms of resistance to cisplatin. Mutation Res 478:23–43PubMed
22.
Zurück zum Zitat Knox RJ, Friedlos F, Lydall DA, Roberts JJ (1986) Mechanism of cytotoxicity of anticancer platinum drugs: Evidence that cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 46:1972–1979PubMed Knox RJ, Friedlos F, Lydall DA, Roberts JJ (1986) Mechanism of cytotoxicity of anticancer platinum drugs: Evidence that cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 46:1972–1979PubMed
23.
Zurück zum Zitat Kollmannsberger C, Rich O, Derigs H-G, Schleucher N, Schoffski P, Beyer J, Schoch R, Sayer HG, Gerl M, Kuczyk C, Spott C, Kanz L, Bokemeyer C (2002) Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 20:2031–2037CrossRefPubMed Kollmannsberger C, Rich O, Derigs H-G, Schleucher N, Schoffski P, Beyer J, Schoch R, Sayer HG, Gerl M, Kuczyk C, Spott C, Kanz L, Bokemeyer C (2002) Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 20:2031–2037CrossRefPubMed
24.
Zurück zum Zitat Kraker A, Schmidt J, Krezoski S, Petering DH (1985) Binding of cis- dichlorodiammine platinum (II) to metallothionoine in Ehrlich cells. Biochem Biophys Res Commun 31:786–792CrossRef Kraker A, Schmidt J, Krezoski S, Petering DH (1985) Binding of cis- dichlorodiammine platinum (II) to metallothionoine in Ehrlich cells. Biochem Biophys Res Commun 31:786–792CrossRef
25.
Zurück zum Zitat Kruidering M, Water BVD, Heer ED, Mulder GJ, Nagelkerrke JF (1997) Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. J Pharmacol Exp Ther 280:638–649PubMed Kruidering M, Water BVD, Heer ED, Mulder GJ, Nagelkerrke JF (1997) Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. J Pharmacol Exp Ther 280:638–649PubMed
26.
27.
Zurück zum Zitat Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X (1997) Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91:479–489CrossRefPubMed Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X (1997) Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91:479–489CrossRefPubMed
28.
Zurück zum Zitat Liu J, Kraut E, Bender J, Brooks R, Balcerzak S, Grever M, Stanley H, D’Ambrosio S, Gibson-D’Ambrosio R, Chan KK (2002) Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients. Cancer Chemo Pharmacol 49:367–374CrossRef Liu J, Kraut E, Bender J, Brooks R, Balcerzak S, Grever M, Stanley H, D’Ambrosio S, Gibson-D’Ambrosio R, Chan KK (2002) Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients. Cancer Chemo Pharmacol 49:367–374CrossRef
29.
Zurück zum Zitat Lynn NN, Howe MC, Hale RJ, Collins GN, O’Reilly PH (2003) Over-expression of metallothionein predicts resistance of transitional cell carcinoma of bladder to intravesical mitomycin therapy. J Urol 169:721–723CrossRefPubMed Lynn NN, Howe MC, Hale RJ, Collins GN, O’Reilly PH (2003) Over-expression of metallothionein predicts resistance of transitional cell carcinoma of bladder to intravesical mitomycin therapy. J Urol 169:721–723CrossRefPubMed
30.
Zurück zum Zitat Nagata S (2000) Apoptotic DNA fragmentation. Exper Cell Res 256:12–18CrossRef Nagata S (2000) Apoptotic DNA fragmentation. Exper Cell Res 256:12–18CrossRef
31.
Zurück zum Zitat Neidle S, Ismail IM, Sadler PJ (1980) The structure of the antitumor complex cis- (diammino) (1,1-cyclobutanedicarboxylato)Pt(II): X ray and nmr studies. J Inorg Biochem 13:205–212CrossRef Neidle S, Ismail IM, Sadler PJ (1980) The structure of the antitumor complex cis- (diammino) (1,1-cyclobutanedicarboxylato)Pt(II): X ray and nmr studies. J Inorg Biochem 13:205–212CrossRef
32.
Zurück zum Zitat Oguri S, Sakakibara T, Mase H, Shimizu T, Ishikawa K, Kimura K, Smyth RD (1988) Clinical pharmacokinetics of carboplatin. J Clin Pharmacol 28:208–215PubMed Oguri S, Sakakibara T, Mase H, Shimizu T, Ishikawa K, Kimura K, Smyth RD (1988) Clinical pharmacokinetics of carboplatin. J Clin Pharmacol 28:208–215PubMed
33.
Zurück zum Zitat Pattanaik A, Bachowski G, Laib J, Lemkuil D, Shaw III F, Petering DH, Hitchcock A, Saryan L (1992) Properties of the reaction of cis-dichlorodiammineplatinum (II) with metallothionein. J Biol Chem 267:16121–16128PubMed Pattanaik A, Bachowski G, Laib J, Lemkuil D, Shaw III F, Petering DH, Hitchcock A, Saryan L (1992) Properties of the reaction of cis-dichlorodiammineplatinum (II) with metallothionein. J Biol Chem 267:16121–16128PubMed
34.
Zurück zum Zitat Pendyala L, Creaven PJ (1993) In vitro cytotoxicity, protein binding, red blood cell partitioning and biotransformation of oxaliplatin. Cancer Res 53:5970–5976PubMed Pendyala L, Creaven PJ (1993) In vitro cytotoxicity, protein binding, red blood cell partitioning and biotransformation of oxaliplatin. Cancer Res 53:5970–5976PubMed
35.
Zurück zum Zitat Petit PX, Zamzami N, Vayssiere JL, Mignotte B, Kroemer G, Castedo M (1997) Implication of mitochondria in apoptosis. Mol Cell Biochem 174:185–188CrossRefPubMed Petit PX, Zamzami N, Vayssiere JL, Mignotte B, Kroemer G, Castedo M (1997) Implication of mitochondria in apoptosis. Mol Cell Biochem 174:185–188CrossRefPubMed
36.
Zurück zum Zitat Prenzler PD, McFadyen WD (1997) Reactions of cisplatin and the cis-diamminediaqua platinum(II) cation with Tris and Hepes. J Inorg Biochem 68:279–282CrossRef Prenzler PD, McFadyen WD (1997) Reactions of cisplatin and the cis-diamminediaqua platinum(II) cation with Tris and Hepes. J Inorg Biochem 68:279–282CrossRef
37.
Zurück zum Zitat Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic C (2002) Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Therap 1:227–235 Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic C (2002) Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Therap 1:227–235
38.
Zurück zum Zitat Reedijk J, Teuben JM (1999) Platinum-sulfur interactions involved in antitumor drugs, rescue agents and biomolecules. In: Lippert B (ed) Cisplatin, chemistry and biochemistry of a leading anticancer drug. weinheim wiley-vch, zurich, pp 319–362 Reedijk J, Teuben JM (1999) Platinum-sulfur interactions involved in antitumor drugs, rescue agents and biomolecules. In: Lippert B (ed) Cisplatin, chemistry and biochemistry of a leading anticancer drug. weinheim wiley-vch, zurich, pp 319–362
39.
Zurück zum Zitat Robson T, Hall A, Lohrer H (1992) Increased sensitivity of a Chinese hamster ovary cell line to alkylating agents after overexpression of the human metallothionein II-A gene. Mutation Res 274:177–185PubMedCrossRef Robson T, Hall A, Lohrer H (1992) Increased sensitivity of a Chinese hamster ovary cell line to alkylating agents after overexpression of the human metallothionein II-A gene. Mutation Res 274:177–185PubMedCrossRef
40.
Zurück zum Zitat Sadowitz PD, Hubbard BA, Dabrowiak JC, Goodisman J, Tacka KA, Aktas MK, Cunningham MJ, Dubowy RL, Souid A-K (2002) Kinetics of cisplatin binding to cellular DNA and modulations by thiol-blocking agents and thiol drugs. Drug Metabol Dispos 30:183–190CrossRef Sadowitz PD, Hubbard BA, Dabrowiak JC, Goodisman J, Tacka KA, Aktas MK, Cunningham MJ, Dubowy RL, Souid A-K (2002) Kinetics of cisplatin binding to cellular DNA and modulations by thiol-blocking agents and thiol drugs. Drug Metabol Dispos 30:183–190CrossRef
41.
Zurück zum Zitat Saika T, Tsushima T, Ochi J, Akebi N, Nau Y, Matsumura Y, Ohmori H (1994) Over-expression of metallothionein and drug-resistance in bladder cancer. Internat J Urol 1:135–139CrossRef Saika T, Tsushima T, Ochi J, Akebi N, Nau Y, Matsumura Y, Ohmori H (1994) Over-expression of metallothionein and drug-resistance in bladder cancer. Internat J Urol 1:135–139CrossRef
42.
Zurück zum Zitat Souid A-K, Tacka Ka, Galvan Ka, Penefsky HS (2003) Immediate effects of anticancer drugs on mitochondrial oxygen consumption. Biochem Pharmacol 66:977–987CrossRefPubMed Souid A-K, Tacka Ka, Galvan Ka, Penefsky HS (2003) Immediate effects of anticancer drugs on mitochondrial oxygen consumption. Biochem Pharmacol 66:977–987CrossRefPubMed
43.
Zurück zum Zitat Souid A-K, Dubowy RL, Blaney SM, Hershon L, Sullivan J, McLeod WD, Bernstein ML (2003) Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors: Children’s Oncology Group trial 9970. Clin Cancer Res 9:703–710PubMed Souid A-K, Dubowy RL, Blaney SM, Hershon L, Sullivan J, McLeod WD, Bernstein ML (2003) Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors: Children’s Oncology Group trial 9970. Clin Cancer Res 9:703–710PubMed
44.
Zurück zum Zitat Tacka KA, Dabrowiak JC, Goodisman J, Penefsky HS, Souid A-K (2004) Quantitative studies on cisplatin-induced cell death. Chem Res Toxicol 17:1102–1111CrossRefPubMed Tacka KA, Dabrowiak JC, Goodisman J, Penefsky HS, Souid A-K (2004) Quantitative studies on cisplatin-induced cell death. Chem Res Toxicol 17:1102–1111CrossRefPubMed
45.
Zurück zum Zitat Tacka KA, Szalda D, Souid A-K, Goodisman J, Dabrowiak JC (2004) Experimental and theoretical studies on the pharmacodynamics of cisplatin in jurkat cells. Chem Res Toxicol 17:1434–1444CrossRefPubMed Tacka KA, Szalda D, Souid A-K, Goodisman J, Dabrowiak JC (2004) Experimental and theoretical studies on the pharmacodynamics of cisplatin in jurkat cells. Chem Res Toxicol 17:1434–1444CrossRefPubMed
46.
Zurück zum Zitat Vaisman A, Lim SE, Patrick SM, Copeland WC, Hinkle DC, Tuchi JJ, Chaney SG (1999) Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts. Biochem 38:11026–11039CrossRef Vaisman A, Lim SE, Patrick SM, Copeland WC, Hinkle DC, Tuchi JJ, Chaney SG (1999) Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts. Biochem 38:11026–11039CrossRef
47.
Zurück zum Zitat Verstraete S, Heudi O, Cailleux A, Allain P (2001) Comparison of the reactivity of oxaliplatin, Pt(diaminocyclohexane) Cl2 and Pt(diaminocyclohexane) (OH2)2 2+ with guanosine and L-methionine. J Inorg Biochem 84:129–135CrossRefPubMed Verstraete S, Heudi O, Cailleux A, Allain P (2001) Comparison of the reactivity of oxaliplatin, Pt(diaminocyclohexane) Cl2 and Pt(diaminocyclohexane) (OH2)2 2+ with guanosine and L-methionine. J Inorg Biochem 84:129–135CrossRefPubMed
48.
Zurück zum Zitat Wyllie AH (1980) Glucorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature (London) 284:555–556CrossRef Wyllie AH (1980) Glucorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature (London) 284:555–556CrossRef
49.
Zurück zum Zitat Yang YY, Robbins PD, Lazo JS (1998) Differential transactivation of human metallothionein-iia in cisplatin-resistant and–sensitive cells. Oncol Res 10:85–98PubMed Yang YY, Robbins PD, Lazo JS (1998) Differential transactivation of human metallothionein-iia in cisplatin-resistant and–sensitive cells. Oncol Res 10:85–98PubMed
50.
Zurück zum Zitat Zamble DB, Lippard SJ (1999) The response of cellular proteins to cisplatin-damaged DNA. In: Lippert B (ed) Cisplatin Chemistry and Biochemistry of a Leading Anticancer Drug. Weinheim Wiley-VCH, Zurich, pp 73–110 Zamble DB, Lippard SJ (1999) The response of cellular proteins to cisplatin-damaged DNA. In: Lippert B (ed) Cisplatin Chemistry and Biochemistry of a Leading Anticancer Drug. Weinheim Wiley-VCH, Zurich, pp 73–110
51.
Zurück zum Zitat Zhang B, Tang W (1994) Kinetics of the reaction of platinum(II) complexes with metallothionein. J Inorg Biochem 56:143–153CrossRefPubMed Zhang B, Tang W (1994) Kinetics of the reaction of platinum(II) complexes with metallothionein. J Inorg Biochem 56:143–153CrossRefPubMed
Metadaten
Titel
Analysis of cytotoxicities of platinum compounds
verfasst von
Jerry Goodisman
Douglas Hagrman
Kirk A. Tacka
Abdul-Kader Souid
Publikationsdatum
01.02.2006
Verlag
Springer-Verlag
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 2/2006
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-005-0041-4

Weitere Artikel der Ausgabe 2/2006

Cancer Chemotherapy and Pharmacology 2/2006 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.